Christoph Zielinski
#23,116
Most Influential Person Now
Austrian physician and oncologist
Christoph Zielinski's AcademicInfluence.com Rankings
Christoph Zielinskiphilosophy Degrees
Philosophy
#6022
World Rank
#8982
Historical Rank
Logic
#3217
World Rank
#4342
Historical Rank
Download Badge
Philosophy
Christoph Zielinski's Degrees
- Doctorate Medicine Medical University of Vienna
- PhD Medical Sciences Medical University of Vienna
Why Is Christoph Zielinski Influential?
(Suggest an Edit or Addition)According to Wikipedia, Christoph Zielinski is an Austrian physician and cancer researcher. A medical oncologist, Zielinski is Director of the Clinical Division of Oncology and Chairman of the Department of Medicine I and the Comprehensive Cancer Centre at the Medical University of Vienna.
Christoph Zielinski's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study (2009) (1114)
- Prediction of venous thromboembolism in cancer patients. (2010) (661)
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015) (627)
- Therapeutic vaccines for cancer: an overview of clinical trials (2014) (610)
- Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. (2009) (532)
- Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. (2018) (485)
- Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. (2008) (463)
- Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. (2008) (437)
- Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. (2015) (436)
- ESMO-Magnitude of Clinical Benefit Scale version 1.1 (2017) (396)
- High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). (2007) (385)
- Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. (2016) (372)
- Oral Mucositis Complicating Chemotherapy and/or Radiotherapy: Options for Prevention and Treatment (2001) (367)
- D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. (2009) (363)
- Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. (2006) (328)
- High D-dimer levels are associated with poor prognosis in cancer patients (2012) (279)
- Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. (2012) (252)
- Microparticle‐associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients (2012) (239)
- Inhibition of metastases by anticoagulants. (1999) (238)
- Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer (2011) (225)
- Third consensus on medical treatment of metastatic breast cancer. (2007) (219)
- Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases (2016) (215)
- High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS) (2010) (213)
- Hypothyroidism in patients with renal cell carcinoma (2011) (206)
- Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. (2011) (205)
- Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants. (2015) (194)
- Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. (2011) (183)
- A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. (2018) (179)
- Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer (2013) (176)
- Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. (2004) (168)
- Brain metastases: pathobiology and emerging targeted therapies (2012) (168)
- Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells. (2008) (167)
- Monitoring of Serum Her-2/neu Predicts Response and Progression-Free Survival to Trastuzumab-Based Treatment in Patients with Metastatic Breast Cancer (2004) (164)
- Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality (2015) (163)
- Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. (2007) (162)
- Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients (2018) (160)
- Global cancer control: responding to the growing burden, rising costs and inequalities in access (2018) (159)
- HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. (1989) (153)
- Contribution of Epigenetic Silencing of Tumor Necrosis Factor–Related Apoptosis Inducing Ligand Receptor 1 (DR4) to TRAIL Resistance and Ovarian Cancer (2005) (153)
- Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. (1997) (149)
- Genome-Wide miRNA Expression Profiling Identifies miR-9-3 and miR-193a as Targets for DNA Methylation in Non–Small Cell Lung Cancers (2012) (148)
- HER 2/neu protein expression in colorectal cancer (2006) (142)
- High Factor VIII Levels Independently Predict Venous Thromboembolism in Cancer Patients: The Cancer and Thrombosis Study (2009) (136)
- Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer (2007) (131)
- Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers (2016) (126)
- Venous thromboembolism and survival in patients with high-grade glioma. (2007) (124)
- Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases (2008) (123)
- Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. (2014) (121)
- Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study (2008) (119)
- Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia. (2010) (112)
- Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. (2010) (111)
- Generation of Peptide Mimics of the Epitope Recognized by Trastuzumab on the Oncogenic Protein Her-2/neu1 (2004) (111)
- Non–Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy (2015) (111)
- Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. (2012) (106)
- Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group. (2005) (106)
- Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. (2009) (104)
- Elevated numbers of immature/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease. (2008) (104)
- T-cell activation in Crohn's disease. Increased levels of soluble interleukin-2 receptor in serum and in supernatants of stimulated peripheral blood mononuclear cells. (1990) (104)
- Five genes from chromosomal band 8p22 are significantly down‐regulated in ovarian carcinoma (2005) (103)
- Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers (2016) (102)
- Lung cancer: From single-gene methylation to methylome profiling (2010) (101)
- NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. (2011) (100)
- Activity of T-DM1 in Her2-positive breast cancer brain metastases (2015) (98)
- Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable (2006) (97)
- Induction of systemic lupus erythematosus by interferon-gamma in a patient with rheumatoid arthritis. (1991) (94)
- HLA-DR antigens in systemic lupus erythematosus: association with specificity of autoantibody responses to nuclear antigens. (1987) (92)
- A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study (2010) (90)
- Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer (2013) (89)
- Angiogenesis in cancer: Anti-VEGF escape mechanisms. (2011) (88)
- Tissue expression and serum levels of HER-2/neu in patients with breast cancer. (1997) (88)
- Soluble HER‐2/neu neutralizes biologic effects of anti‐HER‐2/neu antibody on breast cancer cells in vitro (1997) (86)
- Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. (2005) (86)
- Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis (2011) (85)
- Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer (2007) (85)
- Review of cancer treatment with immune checkpoint inhibitors (2017) (85)
- Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. (2013) (84)
- Cancer stem cells in basic science and in translational oncology: can we translate into clinical application? (2015) (83)
- Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC). (2009) (83)
- Second consensus on medical treatment of metastatic breast cancer. (2007) (83)
- DNA‐methylation analysis identifies the E‐cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies (2004) (81)
- A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma) (2013) (80)
- SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers (2017) (80)
- Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. (2009) (79)
- Circulating procoagulant microparticles in cancer patients (2011) (79)
- Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas (2006) (78)
- Brain metastases free survival differs between breast cancer subtypes (2012) (77)
- Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer. (2000) (77)
- Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). (2014) (76)
- Neoplastic stem cells: A novel therapeutic target in clinical oncology (2006) (76)
- Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group. (1997) (76)
- Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma (2011) (74)
- Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases (2011) (74)
- Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3–05) (2008) (74)
- Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality (2014) (73)
- Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high‐risk B‐cell chronic lymphocytic leukemia (2007) (72)
- Genome-wide CpG island methylation analyses in non-small cell lung cancer patients. (2013) (71)
- Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis (2011) (71)
- Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. (2012) (69)
- Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. (2019) (68)
- 'Blind' antibiotic treatment targeting Chlamydia is not effective in patients with MALT lymphoma of the ocular adnexa. (2006) (68)
- Treatment of extra‐abdominal desmoid tumors with interferon‐alpha with or without tretinoin (2000) (68)
- Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study (2006) (67)
- Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma. (2001) (66)
- Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. (2014) (66)
- Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases (2017) (66)
- Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF: results of a prospective randomised trial. (2001) (66)
- Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion (2018) (65)
- Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality (2015) (65)
- Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression (2006) (65)
- Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study (2013) (65)
- A phase II study of bortezomib in patients with MALT lymphoma (2009) (64)
- Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients – results from the Vienna Cancer And Thrombosis Study (CATS) (2015) (63)
- Perturbation of the Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Cascade in Ovarian Cancer: Overexpression of FLIPL and Deregulation of the Functional Receptors DR4 and DR5 (2005) (62)
- Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). (2014) (62)
- Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment (2003) (61)
- Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her‐2/neu (2003) (59)
- Hypercoagulabilty, venous thromboembolism, and death in patients with cancer (2016) (59)
- Chemotherapy for management of localised high-grade gastric B-cell lymphoma: how much is necessary? (2002) (57)
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2017) (57)
- Activity of Rituximab plus Cyclophosphamide, Doxorubicin/Mitoxantrone, Vincristine and Prednisone in Patients with Relapsed MALT Lymphoma (2007) (57)
- Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. (2004) (57)
- Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer (2005) (56)
- Soluble carcinoembryonic antigen activates endothelial cells and tumor angiogenesis. (2013) (56)
- ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. (2013) (55)
- The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells (2011) (55)
- Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. (2013) (55)
- Paul Ehrlich (1854-1915) and His Contributions to the Foundation and Birth of Translational Medicine (2016) (55)
- High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin. (2003) (55)
- Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. (2016) (54)
- Her‐2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab‐based therapy in patients with metastatic breast cancer (2006) (54)
- Thrombosis risk and survival in cancer patients with elevated C‐reactive protein (2011) (53)
- Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. (2012) (52)
- Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia (2016) (52)
- Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases (2015) (51)
- Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients. (2016) (51)
- Trastuzumab treatment in patients with breast cancer and metastatic CNS disease. (2010) (51)
- Active induction of tumor-specific IgE antibodies by oral mimotope vaccination. (2007) (51)
- Vaccination with a Human High Molecular Weight Melanoma-Associated Antigen Mimotope Induces a Humoral Response Inhibiting Melanoma Cell Growth In Vitro1 (2005) (51)
- Cytoplasmic proteome and secretome profiles of differently stimulated human dendritic cells. (2009) (50)
- Entering a new era of rational biomarker discovery for early detection of melanoma metastases: secretome analysis of associated stroma cells. (2009) (50)
- Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. (2001) (50)
- Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial. (2005) (50)
- Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial. (1998) (49)
- Direct oral anticoagulants compared to low‐molecular‐weight heparin for the treatment of cancer‐associated thrombosis: Updated systematic review and meta‐analysis of randomized controlled trials (2020) (49)
- Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment (2016) (49)
- HER-2-Positive Breast Cancer (2012) (48)
- Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma. (2005) (48)
- Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. (2003) (48)
- Soluble interleukin 2 receptor in acute viral hepatitis and chronic liver disease (1989) (48)
- Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients. (2014) (48)
- Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL. (2020) (46)
- αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer (2014) (46)
- Lytic effector cell activity and major depressive disorder in patients with breast cancer: a prospective study (1995) (46)
- Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF (2007) (46)
- Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study (2022) (46)
- Extracellular matrix remodeling by bone marrow fibroblast-like cells correlates with disease progression in multiple myeloma. (2014) (46)
- Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer (2008) (46)
- Expression of the candidate tumor suppressor gene hSRBC is frequently lost in primary lung cancers with and without DNA methylation (2005) (46)
- Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen. (2005) (45)
- Pretreatment Serum C-Reactive Protein Levels Predict Benefit From Multimodality Treatment Including Radical Surgery in Malignant Pleural Mesothelioma: A Retrospective Multicenter Analysis (2012) (44)
- Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer (2014) (44)
- The European Cancer Patient’s Bill of Rights, update and implementation 2016 (2016) (44)
- CD98hc (SLC3A2) drives integrin-dependent renal cancer cell behavior (2013) (44)
- Proportions of immature CD19+CD21- B lymphocytes predict the response to extracorporeal photopheresis in patients with chronic graft-versus-host disease. (2009) (44)
- FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study. (2013) (43)
- Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study (2004) (43)
- Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed? (2010) (43)
- Intensified local treatment and systemic therapy significantly increase survival in patients with brain metastases from advanced breast cancer - a retrospective analysis. (2006) (42)
- Influenza vaccination perception and coverage among patients with malignant disease. (2015) (42)
- The landscape of medical oncology in Europe by 2020. (2014) (41)
- A catalyst for change: the European cancer Patient's Bill of Rights. (2014) (41)
- Defective macrophage function in a patient with common variable immunodeficiency. (1982) (41)
- Advances in bone tumour treatment in 30 years with respect to survival and limb salvage. A single institution experience (2002) (40)
- Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines. (2001) (40)
- Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tract. (1999) (39)
- Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experience. (2005) (39)
- Interleukin-6 production by peripheral blood monocytes in patients with chronic liver disease and acute viral hepatitis. (1992) (39)
- Collagen Types and Anticollagen-Antibodies in Dupuytren's Disease (1979) (38)
- Matching of trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu--a new method of epitope definition. (2005) (38)
- Lytic effector cell function in schizophrenia and depression (1988) (38)
- Association of platelet activation markers with cancer-associated venous thromboembolism (2016) (38)
- Bevacizumab is active in malignant effusion. (2006) (37)
- Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer. (2004) (37)
- Targeting of VEGF‐dependent transendothelial migration of cancer cells by bevacizumab (2010) (37)
- Gliotoxin is a potent NOTCH2 transactivation inhibitor and efficiently induces apoptosis in chronic lymphocytic leukaemia (CLL) cells (2013) (37)
- Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes (2006) (37)
- Defective antigen presentation resulting from impaired expression of costimulatory molecules in breast cancer (2000) (37)
- A model of experimental post-traumatic osteomyelitis in guinea pigs. (1984) (36)
- 1324PTUMOR-INFILTRATING LYMPHOCYTES (TILS) AND PD-L1 EXPRESSION IN NON- SMALL CELL LUNG CANCER BRAIN METASTASES (BM) AND MATCHED PRIMARY TUMORS (PT). (2014) (35)
- Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment (2006) (35)
- Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). (2014) (34)
- Inhibition of proliferation and induction of apoptosis in soft tissue sarcoma cells by interferon-α and retinoids (1999) (34)
- Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS) (2015) (34)
- Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) (2014) (34)
- Decreased expression of ICAM‐1 and its induction by tumor necrosis factor on breast‐cancer cells in vitro (1997) (34)
- Identification of DLK1 variants in pituitary- and neuroendocrine tumors. (2006) (34)
- Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients (2014) (33)
- The urokinase receptor (CD87) represents a central mediator of growth factor-induced endothelial cell migration (2012) (33)
- Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion (2019) (33)
- Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight‐melanoma associated antigen (HMW‐MAA) specific monoclonal antibody (2005) (33)
- CD98hc (SLC3A2), a novel marker in renal cell cancer (2009) (33)
- Response of a nonmalignant pleural effusion to bevacizumab. (2005) (33)
- Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines (2013) (32)
- Aerobic exercise as additive palliative treatment for a patient with advanced hepatocellular cancer (2003) (32)
- Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders (2021) (32)
- Difference in patient's acceptance of early versus late initiation of psychosocial support in breast cancer (2001) (32)
- Short‐term rhythmic proliferation of human breast cancer cell lines: surface effects and fractal growth patterns (2002) (31)
- High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells (2005) (31)
- Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases—development and validation of the LabBM score (2017) (31)
- Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer (2007) (31)
- Surface phenotypes in T-cell leukaemia are determined by oncogenic retroviruses (1980) (30)
- Immunization with Mimotopes Prevents Growth of Carcinoembryonic Antigen–Positive Tumors in BALB/c Mice (2007) (30)
- Neoplastic stem cells: current concepts and clinical perspectives. (2010) (30)
- CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion (2018) (30)
- Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. (2006) (30)
- Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma (2010) (30)
- Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma. (2015) (30)
- The role of ADAMTS‐13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study (2019) (30)
- Impaired primary, but not secondary, immune response in breast cancer patients under adjuvant chemotherapy (1986) (30)
- Increased serum concentrations of cholesterol and triglycerides in the progression of breast cancer (2004) (30)
- Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. (2016) (29)
- Virus-induced diabetes in mice prevented by a live attenuated vaccine. (1982) (29)
- A functional defect in the early phase of the immune response observed in patients with hemophilia A. (1986) (29)
- Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases (2019) (28)
- Detection of minimal residual disease in patients with cancer: a review of techniques, clinical implications, and emerging therapeutic consequences. (2000) (28)
- Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice (2007) (28)
- Impaired production of tumor necrosis factor in breast cancer (1990) (27)
- Analysis of intrathymic differentiation patterns during the course of AKR leukemogenesis. (1981) (27)
- Effect of estrogen replacement therapy on natural killer cell activity in postmenopausal women. (1996) (27)
- The role of fibrinogen plasma levels, the –455G>A fibrinogen and the factor XIII A subunit (FXIII-A) Val34Leu polymorphism in cancer-associated venous thrombosis (2011) (27)
- FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study. (2015) (27)
- Soluble ICAM-1 in breast cancer: clinical significance and biological implications (2001) (26)
- High‐level ERBB2 gene amplification is associated with a particularly short time‐to‐metastasis, but results in a high rate of complete response once trastuzumab‐based therapy is offered in the metastatic setting (2014) (26)
- Recurrent malignant Triton tumour: first report on a long time survivor. (2003) (26)
- Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. (2012) (26)
- Amplification and overexpression of CMET is a common event in brain metastases of non‐small cell lung cancer (2014) (26)
- Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries (2019) (26)
- Outcome of chemotherapy extravasation in a large patient series using a standardised management protocol (2015) (26)
- Cellular immunodeficiency in protein-losing enteropathy (2005) (26)
- Alleviation of Brain Edema and Restoration of Functional Independence by Bevacizumab in Brain-Metastatic Breast Cancer: A Case Report (2014) (25)
- Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses (2014) (25)
- Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide (2017) (25)
- Statins are associated with low risk of venous thromboembolism in patients with cancer: a prospective and observational cohort study. (2014) (25)
- Deficiences in phenotype expression and function of dentritic cells from patients with early breast cancer. (2006) (25)
- Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring (2021) (25)
- Decreased body mass index is associated with impaired survival in lung cancer patients with brain metastases: A retrospective analysis of 624 patients (2017) (25)
- Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: from pathology to treatment. (2012) (24)
- DNA methylation of microRNA‐coding genes in non‐small‐cell lung cancer patients (2018) (24)
- Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality. (2014) (24)
- Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial (2006) (24)
- Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors (2012) (24)
- Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases. (2006) (24)
- Impact of the Specific Mutation in KRAS Codon 12 Mutated Tumors on Treatment Efficacy in Patients with Metastatic Colorectal Cancer Receiving Cetuximab-Based First-Line Therapy: A Pooled Analysis of Three Trials (2012) (24)
- Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First‐Line Platinum‐Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS‐lung Trial (2017) (23)
- Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer (2009) (23)
- BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy (2014) (23)
- A phase I study of MEDI4736, NNT-PD-L1 antibody in patients with advanced solid tumors. (2014) (23)
- HER-2-positive breast cancer: hope beyond trastuzumab. (2007) (23)
- DNA methylation transcriptionally regulates the putative tumor cell growth suppressor ZNF677 in non-small cell lung cancers (2014) (23)
- A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial (2020) (22)
- Targeting of Hsp32 in solid tumors and leukemias: a novel approach to optimize anticancer therapy. (2009) (22)
- Failure to confirm presence of SV40 sequences in human tumours. (1995) (22)
- Sequential administration of interferon γ and interleukin-2 in metastatic renal cell carcinoma: results of a phase II trial (2000) (22)
- Thymic epithelium is programmed to induce preleukemic changes in retrovirus expression and thymocyte differentiation in leukemia susceptible mice: studies on bone marrow and thymic chimeras. (1982) (22)
- Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status (2001) (22)
- Alterations in intestinal permeability following the intensified polydrug-chemotherapy IFADIC (ifosfamide, Adriamycin, dacarbazine) (2002) (22)
- Presence of varicose veins in cancer patients increases the risk for occurrence of venous thromboembolism (2013) (22)
- Sustained Response to Vemurafenib in a BRAFV600E-Mutated Anaplastic Thyroid Carcinoma Patient. (2016) (22)
- Novel p53-dependent anticancer strategy by targeting iron signaling and BNIP3L-induced mitophagy (2015) (22)
- Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015 (2016) (22)
- Common death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancer. (2005) (21)
- Aldesleukin in advanced renal cell carcinoma (2004) (21)
- The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna (2016) (21)
- Her2 and Progesterone Receptor Status Are Not Predictive of Response to Fulvestrant Treatment (2007) (21)
- Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy. (2009) (21)
- Medroxyprogesterone acetate lowers plasma corticotropin and cortisol but does not suppress anterior pituitary responsiveness to human corticotropin releasing factor (1990) (20)
- Prediction of Venous Thromboembolism in Patients with Cancer By the Activated Partial Thromboplastin Time: Results from the Vienna Cancer and Thrombosis Study (2015) (20)
- PTEN expression in endothelial cells is down-regulated by uPAR to promote angiogenesis (2015) (20)
- A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer. (2003) (20)
- Effect of elevated growth hormone concentrations on the phenotype and functions of human lymphocytes and natural killer cells. (1994) (20)
- Diagnostic value of mucin-like carcinoma-associated antigen (MCA) in breast cancer. (1989) (20)
- Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells. (2015) (20)
- Bevacizumab plus XELOX as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer (2007) (20)
- Gliotoxin Targets Nuclear NOTCH2 in Human Solid Tumor Derived Cell Lines In Vitro and Inhibits Melanoma Growth in Xenograft Mouse Model (2017) (20)
- Effect of elevated serum prolactin concentrations on cytokine production and natural killer cell activity. (1992) (20)
- Risk factors for Clostridium difficile infection in hemato-oncological patients: A case control study in 144 patients (2016) (20)
- Leucocyte migration inhibition with collagen type I and collagen type III in rheumatoid arthritis and degenerative joint diseases. (1978) (19)
- Bevacizumab treatment for advanced breast cancer. (2011) (19)
- Increased natural killer cell activity correlates with low or negative expression of the HER‐2/neu oncogene in patients with breast cancer (1994) (19)
- Intensified adjuvant IFADIC chemotherapy in combination with radiotherapy versus radiotherapy alone for soft tissue sarcoma: long-term follow-up of a prospective randomized feasibility trial (2010) (19)
- Impaired lipopolysaccharide‐inducible tumor necrosis factor production in vitro by peripheral blood monocytes of patients with viral hepatitis (1990) (19)
- Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells (2018) (19)
- Adjuvant systemic therapy for early breast cancer. (2012) (19)
- Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules (2017) (19)
- Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC). (2009) (19)
- Natural killer cell activity and antibody-dependent cellular cytotoxicity in patients under various immunosuppressive regimens. (1987) (19)
- More postchemotherapy rheumatism. (1993) (18)
- Defective macrophage--T-cell interaction in common varied immunodeficiency. (1982) (18)
- Prognostic impact of breast cancer subtypes in elderly patients (2016) (18)
- Regulation of NK cell activity by prostaglandin E2: the role of T cells. (1984) (18)
- Triple-negative breast cancer (2010) (18)
- Absence of efficacy of thalidomide monotherapy in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). (2009) (17)
- A randomised open-label phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC - the ETOP and EORTC SPLENDOUR trial. (2020) (17)
- Uptake of 99mTc-MIBI and 99mTc-tetrofosmin into malignant versus nonmalignant breast cell lines. (2000) (17)
- Increased resting heart rate and prognosis in treatment‐naïve unselected cancer patients: results from a prospective observational study (2020) (17)
- Impact of Her‐2‐Targeted Therapy on Overall Survival in Patients With Her‐2 Positive Metastatic Breast Cancer (2013) (17)
- Defect of Tumour Necrosis Factor-α (TNF-α) Production and TNF-α-induced ICAM-1 – Expression in BRCA1 Mutations Carriers (2003) (17)
- Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG) (2009) (17)
- Effects of adjuvant chemotherapy on specific and non-specific immune mechanisms. (1990) (17)
- Low cholesterol and cancer. (1996) (17)
- Primary pulmonary lymphoma in a patient with the acquired immune deficiency syndrome. (1989) (17)
- Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer. (2012) (17)
- FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study. (2013) (16)
- Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis (2012) (16)
- Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer (2002) (16)
- The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients (2019) (16)
- Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients (2015) (16)
- In vivo tracing of indium-111 oxine-labeled human peripheral blood mononuclear cells in patients with lymphatic malignancies. (1989) (16)
- Soluble interleukin-2 receptor and soluble CD8 antigen in active rheumatoid arthritis. (1990) (16)
- Plasma levels of D-dimer: a crosslinked fibrin-degradation product in female breast cancer. (1991) (16)
- The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients. (2008) (16)
- Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Study ESGAS.1.2.001 (2008) (16)
- Warfarin for cancer prevention. (2000) (16)
- Predictive role of hand–foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer (2015) (16)
- Non-Small Cell Lung Cancer in Countries of Central and Southeastern Europe: Diagnostic Procedures and Treatment Reimbursement Surveyed by the Central European Cooperative Oncology Group. (2018) (15)
- Efficacy of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC). (2017) (15)
- Sequential Administration of Interferon-&ggr;, GM-CSF, and Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma: Results of a Phase II Trial (2001) (15)
- Apolipoprotein A and biological half-life of prostaglandin I2 in HIV-1 infection. (1996) (15)
- Local use of GM-CSF for severe mucositis. (1999) (14)
- Degradation of BRD4 - a promising treatment approach not only for hematologic but also for solid cancer. (2021) (14)
- Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care center (2018) (14)
- Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma. (2016) (14)
- The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) in daily practice: A real-life feasibility analysis at the Medical University Vienna. (2017) (14)
- Comparative 99mTc-MIBI, 99mTc-tetrofosmin and 99mTc-furifosmin uptake in human soft tissue sarcoma cell lines (2000) (14)
- Effects of cyclosporin A upon humoral and cellular immune parameters in insulin-dependent diabetes mellitus type I: a long-term follow-up study. (1989) (14)
- A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors (2020) (14)
- Effective Treatment of Indolent Non-Hodgkin’s Lymphomas with Mitoxantrone, Chlorambucil and Prednisone (2005) (14)
- [Use of plasmapheresis in therapy of systemic lupus erythematosus: a controlled study]. (1988) (14)
- Capecitabine and Vinorelbine as an All-Oral Chemotherapy in HER2-Negative Locally Advanced and Metastatic Breast Cancer (2010) (14)
- Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review. (2012) (13)
- Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma (2003) (13)
- Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D mutated metastatic colorectal cancer (mCRC)? A meta-analysis of 54 cases. (2012) (13)
- Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor. (1998) (13)
- Serum levels of tumour necrosis factor-alpha and interleukin-6 and their correlation with body mass index, weight loss, appetite and survival rate--preliminary data of Viennese outpatients with metastatic cancer during palliative chemotherapy. (2008) (13)
- Second- and third-line treament of metastatic breast cancer with gemcitabine (1998) (13)
- Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer (2005) (13)
- Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis. (2019) (13)
- Vienna International Summer School on Experimental and Clinical Oncology for Medical Students: An Austrian Cancer Education Project (2010) (13)
- Consensus on Medical Treatment of Metastatic Breast Cancer (2003) (13)
- Targeting Receptor Tyrosine Kinases in Cancer (2015) (12)
- Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncology (2019) (12)
- Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity (2006) (12)
- Updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E-mutated anaplastic thyroid cancer (ATC). (2018) (12)
- Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO) (2016) (12)
- Upregulation of retinoic acid receptor‐β by the epidermal growth factor‐receptor inhibitor PD153035 is not mediated by blockade of ErbB pathways (2007) (12)
- Awareness of predatory journals and open access among medical oncologists: results of an online survey (2019) (12)
- Effect of neoadjuvant chemotherapy with gemcitabine and docetaxel on 3-year survival and resection rate in previously unresectable locally advanced pancreatic cancer. (2004) (12)
- ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers (2016) (12)
- Consensus on medical treatment of non-small cell lung cancer. (2002) (12)
- Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer (2000) (12)
- SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients – A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease (2022) (12)
- Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2/neu-Overexpressing Advanced Gastric Cancer—Results from Phase Ib Trial IMU.ACS.001 (2021) (12)
- Survival of women with breast cancer in Austria by age, stage and period of diagnosis. (2002) (11)
- Relation of pro- and anti-inflammatory cytokines and the production of nitric oxide in patients receiving high-dose immunotherapy with interleukin-2. (2000) (11)
- Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma (2012) (11)
- Factors influencing the time to development of brain metastases in breast cancer. (2008) (11)
- Serum associated leucocyte locomotion inhibition and leucocyte motility in malignant melanoma: effect of BCG treatment. (1979) (11)
- Gemcitabine and cisplatin (GC) +/- subsequent maintenance therapy with single-agent gemcitabine in advanced non-small cell lung cancer (NSCLC): Preliminary results of a randomized trial of the Central European Cooperative Oncology Group (CECOG) (2004) (11)
- Effect of carboplatin on the functional integrity of the human sperm membrane in vitro. (2002) (11)
- Long-term influence of adjuvant therapy on natural killer cell activity in breast cancer (2004) (11)
- Cancer immune cycle: a video introduction to the interaction between cancer and the immune system (2016) (11)
- Intensified Adjuvant IFADIC Chemotherapy for Adult Soft Tissue Sarcoma: A Prospective Randomized Feasibility Trial (2000) (11)
- Lytic effector cell function following kidney transplantation. (1987) (11)
- Vinorelbine and interferon-α2c as second-line therapy in metastatic renal cell carcinoma (2000) (11)
- Defect of tumour necrosis factor-alpha (TNF-alpha) production and TNF-alpha-induced ICAM-1-expression in BRCA1 mutations carriers. (2003) (11)
- Therapy of small cell lung cancer with emphasis on oral topotecan. (2010) (11)
- A Cross-Sectional Study of Patients' Satisfaction With Totally Implanted Access Ports. (2016) (10)
- Case report: impressive response to pembrolizumab in a patient with mismatch-repair deficient metastasized colorectal cancer and bulky disease (2016) (10)
- Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer (2014) (10)
- Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines. (2009) (10)
- Neoadjuvant chemotherapy including bevacizumab in potentially curable metastatic colorectal cancer. (2006) (10)
- Acute-phase-proteins and parameters of humoral immunity in patients with advanced Hodgkin's disease (2004) (10)
- Temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma: Preliminary results from the Austrian Compassionate Use Program (2008) (10)
- Gemcitabine, anthracycline, and taxane combinations for advanced breast cancer. (2003) (10)
- ROAR: a phase 2, open-label study in patients (pts) with BRAF V600E–mutated rare cancers to investigate the efficacy and safety of dabrafenib (D) and trametinib (T) combination therapy. (2016) (10)
- The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer (2009) (10)
- Systemic Lupus Erythematosus: Clinical and Experimental Aspects (1987) (10)
- A randomized, open-label CECOG phase II study evaluating the efficacy and safety of FOLFOX6 + cetuximab versus FOLFIRI + cetuximab as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC) (2008) (9)
- Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter, community-based feasibility trial (2001) (9)
- Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC). (2011) (9)
- Sequential Administration of Interferon-gamma, GM-CSF, and Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma: Results of a Phase II Trial. (2001) (9)
- Rituximab, Ara-C, Dexamethasone and Oxaliplatin Is Safe and Active in Heavily Pretreated Patients with Diffuse Large B-Cell Lymphoma (2006) (9)
- Sequential administration of interferon gamma and interleukin-2 in metastatic renal cell carcinoma: results of a phase II trial. Austrian Renal Cell Carcinoma Study Group. (2000) (9)
- New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series (2019) (9)
- Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine (2008) (9)
- PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer (2017) (9)
- CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion (2019) (9)
- A HIGH PLATELET COUNT INDEPENDENTLY PREDICTS VENOUS THROMBOEMBOLISM IN CANCER PATIENTS (2007) (9)
- Plasma levels ofd-Dimer: a crosslinked fibrin-degradation product in female breast cancer (2005) (9)
- Breast cancer, locally advanced and metastatic (2012) (9)
- Nonsurgical management of gallbladder cancer: cytotoxic treatment and radiotherapy (2001) (9)
- Correcetions to "A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)". (2017) (9)
- Defining risk status in the first-line treatment of metastatic renal cell carcinoma (2010) (8)
- What are the current standards of care and recent developments in the management of breast cancer? (2006) (8)
- Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancer patients. (2001) (8)
- Serum osteocalcin levels in breast cancer patients (2004) (8)
- Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): Preliminary safety data from the CECOG phase III TURANDOT trial. (2010) (8)
- The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status (2005) (8)
- Management of cardiac adverse events occurring with sunitinib treatment. (2009) (8)
- Gemcitabine, epirubicin and paclitaxel (GET) vs. 5-fluorouracil, epirubicin and cyclophosphamide (FEC) as first-line treatment in metastatic breast cancer: interim toxicity analysis of a randomised, multicenter phase iii trial of the Central European Cooperative Oncology Group (CECOG) (2001) (8)
- Consensus on the medical treatment of colon cancer (2008) (8)
- GDF‐15 in solid vs non‐solid treatment‐naïve malignancies (2019) (8)
- Tolerability of pemetrexed versus placebo as a maintenance therapy in advanced non-small cell lung cancer: Evidence from a large randomized study (2008) (8)
- Abstract OT2-01-06: Phase III study of palbociclib (PD-0332991) in combination with endocrine therapy (exemestane or fulvestrant) versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with resistance to aromatase inhibitors.“The P (2017) (8)
- Marked Activity of Bortezomib, Rituximab, and Dexamethason in Relapsed and Refractory Mantle Cell Lymphoma. (2006) (8)
- Plaque-forming cells in human cord blood: studies on T and B cell function. (1980) (8)
- Decreased production of soluble interleukin 2 receptor by phytohaemagglutinin-stimulated peripheral blood mononuclear cells in patients with breast cancer after adjuvant therapy. (1989) (8)
- CA184-156: Randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) plus etoposide/platinum (EP) versus placebo plus EP in patients (Pts) with newly diagnosed extensive-stage disease small cell lung cancer (ED-SCLC). (2012) (8)
- Subclinical involvement of the liver is associated with prognosis in treatment naïve cancer patients (2017) (8)
- Progression-free survival in a phase II study of perioperative bevacizumab plus XELOX in patients with potentially curable metastatic colorectal cancer (2008) (8)
- Pandemic whole-virion, Vero-cell-derived, adjuvant-free influenza A H1N1 vaccine in patients with solid tumors and hematologic malignancies receiving concurrent anticancer treatment: Immunogenicity, tolerability, and acceptability during the pandemic situation. (2012) (8)
- A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial. (2018) (8)
- Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI (2019) (7)
- Nab-paclitaxel as alternative treatment regimen in advanced cholangiocellular carcinoma. (2016) (7)
- Zoledronate in a patient with pamidronate refractory hypercalcemia syndrome (2003) (7)
- Defects of leukocyte locomotion in multiple myeloma. (1982) (7)
- Phenotypic and functional analysis of cellular cytotoxicity after splenectomy. (1988) (7)
- Efficacy of first-line bevacizumab (BEV)-based therapy for metastatic triple-negative breast cancer (TNBC): Subgroup analysis of TURANDOT. (2013) (7)
- [Combined therapy with cyclosporin A and cortisone in endocrine Basedow endocrine orbitopathy: successful use in compressive optic neuropathy]. (1993) (7)
- VMCP chemotherapy with or without interferon-alpha-2 in newly diagnosed patients with multiple myeloma. (1989) (7)
- ADJUVANT CHEMOTHERAPY COMBINED WITH TAMOXIFEN IN POSTMENOPAUSAL PATIENTS WITH STAGE II BREAST CANCER (1986) (7)
- The DNA-binding epidermal growth factor-receptor inhibitor PD153035 and other DNA-intercalating cytotoxic drugs reactivate the expression of the retinoic acid receptor-beta tumor-suppressor gene in breast cancer cells. (2007) (7)
- Abstract P3-11-06: Bevacizumab in combination with docetaxel+trastuzumab +/- non-pegylated liposomal doxorubicin: Final results of ABCSG-32, a prospective, randomized phase II-study (2015) (7)
- Expression of thymidine phosphorylase in peripheral blood cells of breast cancer patients is not increased by paclitaxel (2007) (7)
- Gemcitabine and cisplatin (GC) +/- subsequent maintenance therapy with single-agent gemcitabine in advanced non-small cell lung cancer (NSCLC): Preliminary results of a randomized trial of the Central European Cooperative Oncology Group (CECOG). (2003) (7)
- Absent antibody production following COVID19 vaccination with mRNA in patients under immunosuppressive treatments (2021) (7)
- Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel (2010) (7)
- Transient immunoglobulin and antibody production. Occurrence in two patients with common varied immunodeficiency. (1983) (7)
- Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancer. (2012) (7)
- A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer. (2007) (7)
- Divergent patterns of leucocyte locomotion in experimental post-traumatic osteomyelitis. (1984) (7)
- Effects of cilengitide in osteoclast maturation and behavior. (2015) (7)
- Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease (2013) (7)
- Effect of immunoglobulin substitution during plasmapheresis on serum immunoglobulin and complement concentrations. (1985) (7)
- p53 adapted neoadjuvant therapy for esophageal cancer: Pilot study (2007) (7)
- Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in patients with early breast cancer: results from a randomised study of the Central European Cooperative Oncology Group (CECOG) (2008) (7)
- Subclinical involvement of the liver is associated with prognosis in treatment naïve cancer patients. (2017) (7)
- Divide and conquer: Rat liver tissue proteomics based on the analysis of purified constituents (2006) (7)
- Reduced mitogenic stimulation of peripheral blood mononuclear cells as a prognostic parameter for the course of breast cancer (1994) (7)
- Correlation of clinical outcome with p53 and p21 status in patients with advanced transitional-cell carcinoma treated with paclitaxel and carboplatin. (2002) (6)
- Durable remissions after rituximab plus thalidomide for relapsed/refractory mantle cell lymphoma. (2004) (6)
- Gemcitabine/anthracycline combinations in metastatic breast cancer. (2002) (6)
- Reduced production of immunoreactive interleukin-1 by peripheral blood monocytes of patients with acute and chronic viral hepatitis (1993) (6)
- Hepatic Dysfunction Contributes to Coagulation Disturbances in Patients Undergoing whole Body Hyperthermia by Use of Extracorporeal Circulation (2014) (6)
- Gastrointestinal tumors, non-colorectal (2012) (6)
- FOLFOX4 plus cetuximab administered weekly or every two weeks in first-line treatment of patients with KRAS and NRAS wild-type (wt) metastatic colorectal cancer (mCRC). (2014) (6)
- Arterial hepatic embolization of unresectable hepatocellular carcinoma using a cyanoacrylate/lipiodol mixture (1998) (6)
- Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu– positive advanced breast cancer: results of the CECOG LaVie trial (2016) (6)
- Prinzmetal's angina during cyclophosphamide therapy. (1988) (6)
- Impaired hemorheology in patients with postmastectomy lymphedema (2005) (6)
- [Aerobic endurance training for cancer patients]. (2003) (6)
- CD98hc (SLC3A2) drives integrin-dependent renal cancer cell behavior (2013) (6)
- Major response and clinical benefit following third-line treatment for Bellini duct carcinoma (2004) (6)
- Verapamil decreases accumulation of 99Tcm-MIBI and 99Tcm-tetrofosmin in human breast cancer and soft tissue sarcoma cell lines (2001) (6)
- Monotherapy with docetaxel in second- or third-line treatment of anthracycline-resistant metastatic breast cancer. (2000) (6)
- Indocyanine Green Video Angiography Predicts Outcome of Extravasation Injuries (2014) (6)
- Cardiac involvement in patients with sorafenib or sunitinib treatment for metastatic renal cell carcinoma (2007) (6)
- Natural killer cell activity in long term survivors of testicular cancer. Influence of cytostatic therapy and initial stage of disease (1995) (6)
- Single‐agent gemcitabine as second‐ and third‐line treatment in metastatic breast cancer (2000) (5)
- Marked activity of bortezomib, rituximab, and dexamethasone (BORID) in heavily pretreated patients with mantle cell lymphoma. (2006) (5)
- Correlation of KRAS status with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated first-line with FOLFOX6 + cetuximab (FX+C) or FOLFIRI + cetuximab (FF+C): The CECOG/CORE1.2.001 trial. (2009) (5)
- Abstract P6-14-05: Final Overall Survival Analysis of the TBP Phase III Study (GBG 26/BIG 3-05): Capecitabine vs. Capecitabine + Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing during Trastuzumab Treatment (2010) (5)
- Long-term follow-up of patients with Graves' orbitopathy treated by plasmapheresis and immunosuppression. (1989) (5)
- Darbepoetin alpha as treatment for anemia in patients receiving chemotherapy: a single-center experience. (2005) (5)
- Pilot study on sex hormone levels and fertility in women with malignant gliomas (2012) (5)
- SERPINB7 Expression Predicts Poor Pancreatic Cancer Survival Upon Gemcitabine Treatment (2018) (5)
- [Tumor stem cell research - basis and challenge for diagnosis and therapy]. (2010) (5)
- Oral vinorelbine in the treatment of advanced breast cancer (2004) (5)
- Novel agents have a significant impact on survival of patients with multiple myeloma (2015) (5)
- Awareness and understanding of cancer immunotherapy in Europe (2014) (5)
- Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease. Results of the CECOG-Study ESGAS.1.2.001 (2007) (5)
- Mechanism of leukocyte locomotion in hemophilia. (1980) (5)
- [Use of trastuzumab in the therapy of breast cancer]. (2008) (5)
- PD1 and PD-L1 expression in glioblastoma. (2014) (5)
- RESILIENT: Study of irinotecan liposome injection (nal-IRI) in patients with small cell lung cancer—Preliminary findings from part 1 dose-defining phase. (2019) (5)
- The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna (2017) (5)
- Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer. (2020) (5)
- Viral reactivation as a cause of unexplained fever in patients with progressive metastatic breast cancer (2005) (5)
- Consensus on medical treatment of non-small cell lung cancer (2002) (5)
- Influence of hip arthroplasty upon chemotactic behaviour of leucocytes. (1982) (4)
- Effectiveness of neoadjuvant chemotherapy including bevacizumab in patients with resectable colorectal cancer liver metastases (2007) (4)
- Spontaneous and interferon-induced natural cytotoxicity in Crohn's disease. (1988) (4)
- Rapid Remission Induction by VTD (Velcade, Thalidomide, Dexamethason) in Patients with Multiple Myeloma and High Tumor Burden at Diagnosis. (2007) (4)
- A phase I study to evaluate safety, immunogenicity and antitumor activity of a HER2 multi-peptide virosome vaccine in patients with metastatic breast cancer (2008) (4)
- Limitations of cancer care in Central and South-Eastern Europe: results of the international conference organized by the Central European Cooperative Oncology Group (CECOG) (2020) (4)
- Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry. (2014) (4)
- Transient increase in mitogen-induced lymphoproliferative responses in patients with testicular cancer after BEP chemotherapy. (2000) (4)
- Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel (2017) (4)
- Changes in Mcl-1 expression in rectal cancer in relation to neo-adjuvant radiotherapy (2005) (4)
- Dialyzable leukocyte extract (transfer factor) in the treatment of superinfected fistulating tuberculosis of the bone. (1984) (4)
- Collagenase-induced experimental arthritis. (1979) (4)
- Plasma PD-L1 concentration in patients with brain metastases from solid tumors. (2015) (4)
- Adjuvant tamoxifen in postmenopausal stage II breast cancer five years on (1990) (4)
- Bortezomib, Rituximab, and Dexamethason (BORID) as Salvage Treatment in Relapsed/Refractory Mantle Cell Lymphoma: Sustained Disease Control in Patients Achieving a Complete Remission. (2007) (4)
- Reduced seroprevalence against vaccine preventable diseases (VPDs) in adult patients with cancer: necessity of routine vaccination as part of the therapeutic concept. (2020) (4)
- The cancer survival index—A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies (2022) (4)
- Targeting Nuclear NOTCH2 by Gliotoxin Recovers a Tumor-Suppressor NOTCH3 Activity in CLL (2020) (4)
- [Effect of various factors on survival after recurrent and/or metastatic breast cancer]. (1991) (4)
- Preoperative second-line chemotherapy induces objective responses in primary breast cancer. (2005) (4)
- Asialo GM1, as a cell-surface marker in acute lymphoblastic leukemia. (1981) (4)
- Fulvestrant (FUL) and goserelin (GOS) in premenopausal women with advanced, hormone-sensitive breast cancer: A pilot study (2005) (4)
- Predictive Value of D-Dimer Levels for Venous Thromboembolism in Cancer Patients: Results from the Vienna Cancer and Thrombosis Study (CATS) (2008) (4)
- Abstract PD2-4: Subgroup efficacy analyses of the randomized phase III TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC) (2015) (4)
- Abstract P3-06-08: Plasma (p) biomarker results from the TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative metastatic breast cancer (mBC) (2015) (4)
- Leukocyte locomotion and regulative serum effects in rheumatoid arthritis. (1981) (4)
- 2-YEARS EXPERIENCE WITH PACLITAXEL/CARBO- PLATIN AS FIRST LINE THERAPY IN METASTATIC BLADDER CANCER (1999) (4)
- Single-agent trastuzumab versus trastuzumab plus cytotoxic chemotherapy in metastatic breast cancer: a single-institution experience (2005) (4)
- Whole Body Hyperthermia by Extracorporeal Circulation in Spontaneously Breathing Sarcoma Patients: Hemodynamics and Oxygen Metabolism (2011) (4)
- Reply to the letter to the editor 'The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice' by Hartmann and the letter 'Comment on ESMO Magnitude of Clinical Benefit Scale' by Muhonen et al. (2016) (4)
- Natural Immunity in Schizophrenia (1987) (3)
- Delay in time to worsening of symptoms (TWS) of advanced non-small cell lung cancer (NSCLC) using gemcitabine (gem) maintenance therapy. (2006) (3)
- Abstract P5-17-03: Quality of life (QoL) results from the TURANDOT trial comparing two bevacizumab (BEV)-containing regimens as first-line treatment for HER2-negative metastatic breast cancer (mBC) (2012) (3)
- Brain metastasis-free survival in patients with HER2-positive metastatic breast cancer. (2011) (3)
- Evaluating the impact of relative total dose intensity (RTDI) on patient's short- and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer: A pooled analysis. (2009) (3)
- CECOG educational illustrations: the blood–brain barrier and its relevance for targeted cancer therapies and immuno-oncology (2017) (3)
- [The function of lytic effector cells in schizophrenic patients]. (1988) (3)
- Unilateral face swelling as first manifestation of metastatic pancreatic cancer: Case report and review of the literature (2008) (3)
- Palifermin and chemotherapy-induced oral mucositis. (2005) (3)
- Description of Systemic Lupus Erythematosus: A Historical Perspective (1987) (3)
- Urokinase Receptor (uPAR)-Dependent Integrin Redistribution Represents a Central Mechanism for Growth Factor Induced Endothelial Cell Migration (2010) (3)
- Defective interferon-augmented natural killer cell activity in patients with metastatic malignant melanoma (2004) (3)
- Novel p 53-dependent anticancer strategy by targeting iron signaling and BNIP 3 L-induced mitophagy (2015) (3)
- Amplification of 1q21 Is Associated with Poor Outcome after Treatment with Bortezomib in Relapsed/Refractory Multiple Myeloma. (2006) (3)
- Re: International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. (2010) (3)
- Increased expression of Ia antigens on thymocytes from late preleukemic and leukemic AKR mice (2004) (3)
- Con A-induced suppressor cells in children with acute lymphoblastic leukaemia. (1980) (3)
- Monitoring of Serum (2009) (3)
- Prognostic and predictive value of ESR1 mutations in postmenopausal metastatic breast cancer (MBC) patients (pts) resistant to aromatase inhibitors (AI), treated with palbociclib (PAL) in combination with endocrine therapy (ET) or capecitabine (CAP) in the PEARL study. (2020) (3)
- Pemetrexed is more effective in patients with nonsquamous non-small cell lung cancer (NSCLC) histology: an analysis of three large, randomized, phase III trials (2009) (3)
- Adjuvant docetaxel plus cisplatin in stage I/II non-small cell lung cancer (NSCLC): Preliminary results of a randomized phase II pilot trial of the Central European Cooperative Oncology Group (CECOG) (2004) (3)
- 229MO Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study (2021) (3)
- Active immunization with a Her-2/neu-targeting Multi-peptide B cell vaccine prevents lung metastases formation from Her-2/neu breast cancer in a mouse model (2022) (3)
- Trastuzumab (T) plus capecitabine (C) in heavily pretreated patients (pts) with advanced breast cancer (ABC) (2007) (3)
- CSF cytology of a patient with conversion of an acute lymphatic leukemia to an acute eosinophilic leukemia. (1986) (3)
- Evaluation of invasion patterns and their correlation with integrin alphavbeta expression in brain metastases of solid cancers. (2013) (3)
- Functional activity of peripheral mononuclear cells in cystic fibrosis: antibodies and plaque formation. (1982) (3)
- Preliminary results of a pilot-trial with trastuzumab + weekly epidoxorubicin/docetaxel in the neoadjuvant treatment of primary, operable breast cancer (2003) (2)
- The Hsp32/HO-1-targeted drug SMA-ZnPP counteracts the proliferation and viability of neoplastic cells in solid tumors and hematologic neoplasms (2007) (2)
- Predictive role of carcinoembryonic antigen (CEA) for therapeutic efficacy of angiogenesis-targeting therapy in colorectal cancer: Novel clinical observation based upon recently discovered CEA biology. (2010) (2)
- Prolonged decrease in mitogenic stimulation of peripheral blood mononuclear cells following adjuvant chemotherapy, but not under tamoxifen, in stage II breast cancer (1992) (2)
- T-DM1 in HER2-positive breast cancer brain metastases (BM). (2014) (2)
- Lumiliximab Triggers Apoptosis Mechanisms in CLL Cells through the Inhibition of PI3-K/Akt Pathway. (2009) (2)
- Plaque-forming cells in human cord blood: a soluble factor suppressing differentiation but not proliferation of B cells. (1982) (2)
- [Significance of hormone receptors of breast cancer cells for the duration of a disease-free interval]. (1985) (2)
- Comparative 99mTc-MIBI, 99mTc-tetrofosmin and 99mTc-furifosmin uptake in human soft tissue sarcoma cell lines. (2000) (2)
- [The influence of metabolic control on chemotactic activity in insulin-dependent diabetes mellitus (author's transl)]. (1978) (2)
- Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives (2018) (2)
- Two types of human Th17 cells with pro- and anti-inflammatory properties and distinct roles in autoinflammation (2015) (2)
- Benefit of interferon-α2b in a patient with unresectable hepatoma and chronic infection with hepatitis C virus (2000) (2)
- Hypermethylation of N33 (TUSC3) as independent molecular predictor for ovarian cancer (2006) (2)
- N33 (TUSC3) promoter hypermethylation in serum of prostate cancer patients (2006) (2)
- Increased Fc-receptor-mediated clearance via reticuloendothelial system in patients with nephrotic syndrome. (1991) (2)
- Awareness and understanding of cancer immunotherapy in Europe. (2013) (2)
- MEDICAL RADIATION THERAPIES (2013) (2)
- Treatment Choices for Second-Line Chemotherapy of Metastatic Breast Cancer (2003) (2)
- Correlation of plasma PD-L1 detectability with age in glioma patients. (2015) (2)
- Preoperative second-line chemotherapy induces objective responses in primary breast cancer (2004) (2)
- Acute autoimmune collagen-induced arthritis in rabbits. (1978) (2)
- The EXACT trial: An individualized treatment protocol for solid tumors. (2014) (2)
- Access to Novel Drugs for Non‐Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis (2019) (2)
- AIOM chooses ESMO Open—Cancer Horizons as its official journal: a warm welcome from ESMO Open (2016) (2)
- Feasibility of personalized treatment concepts in gastrointestinal malignancies: Sub-group results of prospective clinical phase II trial EXACT (2018) (2)
- 442 Fulvestrant (‘Faslodex’) demonstrates clinical benefit in heavily pre-treated patients with metastatic breast cancer (2003) (2)
- 1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC) (2015) (2)
- Adequacy of anticipatory anxiety in women receiving chemotherapy for breast cancer (2005) (2)
- Effective Targeting of the PI3-K Pathway in CLL with NVP-BEZ235, a Novel Orally Available Dual PI3K/mTOR Inhibitor (2008) (2)
- [Informed consent and responsibility for patient education in oncology. Review of Austrian and German jurisprudence]. (2000) (2)
- 45 Ovarian Function Suppression Plus Fulvestrant in Premenopausal Women with Metastatic Breast Cancer (2012) (2)
- Nab-paclitaxel as second-line treatment in advanced biliary cancer. (2015) (2)
- A prospective, open-label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first-line chemotherapy in patients with androgen-independent prostate cancer (2005) (2)
- Defective leukocyte locomotion in cystic fibrosis. (1982) (2)
- PO-01 - Congestive heart failure is an independent risk factor for venous thromboembolism and mortality in cancer patients. (2016) (2)
- Safety and efficacy of axitinib in pretreated patients with metastatic renal cell carcinoma: A single center experience of the Medical University of Vienna, Austria. (2013) (2)
- ATG overdose in a kidney-grafted patient (1988) (2)
- Partial Characterization and In Vitro Expansion of Putative CLL Precursor/Stem Cells Which Are Dependent on Bone Marrow Microenvironment for Survival (2010) (2)
- 3064 POSTER Neoadjuvant bevacizumab plus XELOX is feasible in patients with potentially curable metastatic colorectal cancer receiving synchronous resection (2007) (2)
- Efficacy of docetaxel in the second-line treatment of locally advanced or metastatic soft tissue sarcoma after failure of chemotherapy with anthracycline or ifosfamide. (1999) (2)
- Oral vinorelbine in the treatment of advanced breast cancer. (2004) (2)
- ATG overdose in a kidney‐grafted patient: Clinical course and possible implications (1988) (2)
- Regorafenib therapy in metastatic colorectal cancer patients: markers and outcome in an actual clinical setting. (2018) (2)
- Anti‐HER‐2/NEU antibody induces apoptosis in HER‐2/NEU overexpressing breast cancer cells independent from intact P53 (2000) (2)
- Coexpression of HER3 as a predictor of survival in HER2-positve breast cancer patients. (2013) (2)
- A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer (2019) (2)
- Noninferiority on overall survival of every-2-weeks vs weekly schedule of cetuximab for first-line treatment of RAS wild-type metastatic colorectal cancer (2019) (2)
- P2.12-04 Liposomal Irinotecan vs Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed On/After Platinum-Based Therapy (2018) (2)
- Asymptomatic cholangitis with the acquired immuno-deficiency syndrome. Clinical and diagnostic features. (1986) (1)
- Medical and Neuro-Oncology (2010) (1)
- [Interferon therapy in multiple myeloma]. (1988) (1)
- Predicting response to second-line trastuzumab-based therapy in patients (pts) with HER2-positive advanced breast cancer (ABC). (2009) (1)
- Educational video: the role of PD-L1 in the local tumour microenvironment (2016) (1)
- Promising Activity of Bortezomib, Rituximab, and Dexamethason (BORID) in Patients with Relapsed Mantle Cell Lymphoma. (2005) (1)
- Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. (2012) (1)
- 353OEFFICACY AND SAFETY IN TANIA, A RANDOMISED PHASE III TRIAL OF CONTINUED OR REINTRODUCED BEVACIZUMAB (BEV) AFTER 1ST-LINE BEV FOR HER2-NEGATIVE LOCALLY RECURRENT/METASTATIC BREAST CANCER (LR/MBC). (2014) (1)
- Health-related quality of life (HQOL) and early survival outcome of the randomized adjuvant dose-dense (dd) FEC75 versus FEC90 CECOG study. (2010) (1)
- Benefit of interferon-alpha2b in a patient with unresectable hepatoma and chronic infection with hepatitis C virus. (2000) (1)
- Die Interferontherapie beim multiplen Myelom (1988) (1)
- 2095 POSTER A randomized, open-label CECOG phase II study of dose-dense FEC 75 vs FEC 90 as adjuvant therapy in early breast cancer patients (2007) (1)
- A Cellular Proteome Map of Human Multiple Myeloma. (2007) (1)
- OS7.4 Outcome of patients presenting with brain metastasis as first manifestation of cancer (2016) (1)
- Association of tumor-infiltrating lymphocytes with brain edema and overall survival in brain metastases. (2014) (1)
- Adjuvant tamoxifen in postmenopausal patients with breast cancer and negative axillary lymph nodes. (1992) (1)
- Inhibition of NOTCH Activity by GLIOTOXIN Induces Apoptosis in CLL Cells and Overcomes the Supportive Effect of Primary Bone Marrow Stromal Cells (2011) (1)
- Life quality and subjective feeling with additional homeopathic treatment in cancer patients (2009) (1)
- [Breast-preserving treatment of breast carcinoma]. (1989) (1)
- Primary tumor sidedness associates with prognosis of patients with brain metastases of colorectal cancer. (2017) (1)
- ESMO Open—Cancer Horizons and the future of oncology (2015) (1)
- Pirarubicin(4′-0-Tetrahydropyranil-Doxorubicin) for Treatment of Metastatic Breast Cancer (1989) (1)
- Abstract P2-08-17: Prognostic impact of breast cancer subtypes in elderly patients (2016) (1)
- Comprehensive results of a phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer (2019) (1)
- 5061 POSTER Impact of Systemic Anti-Her2 Treatment on Overall Survival in Patients With Brain Metastases From Her2-overexpressing Breast Cancer (2011) (1)
- Disturbance of B-Cell Homeostasis In Chronic Graft-Versus-Host Disease of the Lung (2010) (1)
- Plasmapheresis in patients with familial hypercholesterolemia lowers ionized calcium but does not deteriorate left ventricular function. (1990) (1)
- Development and validation of a clinical prediction model for cancer-associated venous thromboembolism in two independent prospective cohorts (2020) (1)
- Recurrent pyoderma in a family with a defect in leucocyte locomotion (1985) (1)
- Secretome Analyses of Primary Bone Marrow Fibroblasts Isolated From MGUS and Multiple Myeloma Show a Stepwise Occurrence of Alterations. (2009) (1)
- 7106 POSTER DISCUSSION The Proteasome-inhibitor Bortezomib is Active in Human Urothelial Cancer Cell Lines in Combination With the Tyrosine-kinase Inhibitor Sunitinib or Cisplatinum (2011) (1)
- 580 Prostate cancer apoptosis in androgen dependent and independent cell cultures harvested from in vivo specimen (2004) (1)
- Expression and secretion of VEGF in solid tumor cells is mediated by the mammalian target of rapamycin (mTOR) (2007) (1)
- 5058 Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial (2009) (1)
- Feasibility of docetaxel, epirubicin, and capecitabine (TEX) plus pegfilgrastim as neoadjuvant treatment for primary breast cancer: A pilot stud. (2004) (1)
- RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration. (2018) (1)
- Phase III study of Palbociclib in combination with Exemestane vs. Capecitabine, in Hormonal Receptor (HR) positive/HER2 negative Metastatic Breast Cancer (MBC) patients with Resistance to non-steroidal Aromatase inhibitors (NSAI): PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006) (2015) (1)
- Treatment of metastatic breast cancer: a historical perspective (2008) (1)
- [Spontaneous and interferon-induced activity of natural killer cells in patients with liver cirrhosis and chronic active hepatitis]. (1987) (1)
- Modulation of leucocyte locomotion by interleukin‐1 (1990) (1)
- Present and future breast cancer management-bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry. (2014) (1)
- Functional role of 4F2hc in pancreatic ductal adenocarcinoma (2016) (1)
- AUSSAGEKRAFT DES CARCINO-EMBRYONALEN ANTIGENS (1995) (1)
- Recurrent pyoderma in a family with a defect in leucocyte locomotion. (1984) (1)
- Sequential chemotherapy with estramustine and vinorelbine for tumour cell synchronization in hormone refractory prostate cancer (2003) (1)
- [Detection of collagenase in passive haemagglutination using collagen-coated erythrocytes (author's transl)]. (1978) (1)
- The Chromosomal Pattern 14q-Translocation Plus 13q-Deletion Is Characteristic for Multiple Myeloma after a Preceding Monoclonal Gammopathy of Undetermined Significance. (2004) (1)
- Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer (2022) (1)
- Vaccination with trastuzumab epitope mimics leads to prolonged tumor-free survival in HER-2/neu transgenic mice (2006) (1)
- Potential of biologically targeted therapies for breast cancer (2006) (1)
- A cross-section study evaluating patients’ satisfaction with totally implanted access ports (PAC) assessing the PAC-related complication rate at two tertiary care centres in Austria. (2014) (1)
- 409TiPPHASE III STUDY OF PALBOCICLIB IN COMBINATION WITH EXEMESTANE VS. CAPECITABINE, IN HORMONAL RECEPTOR (HR) POSITIVE/HER2 NEGATIVE METASTATIC BREAST CANCER (MBC) PATIENTS WITH RESISTANCE TO NON-STEROIDAL AROMATASE INHIBITORS (NSAI): PEARL STUDY (GEICAM/2013-02_CECOG/BC.1.3.006). (2014) (1)
- Her-2/neu as Predictive Marker for Endocrine Therapy and Chemotherapy in Patients with Metastatic Breast Cancer (2003) (1)
- Adjuvant docetaxel plus cisplatin in stage I/II non-small cell lung cancer (NSCLC): Preliminary results of a randomized phase II pilot trial of the Central European Cooperative Oncology Group (CECOG). (2004) (1)
- Recent developments and translational aspects in targeted therapy for metastatic breast cancer (2016) (1)
- 2927 Programmed death ligand 1 (PD-L1) expression and tumor infiltrating lymphocytes in diffuse and anaplastic gliomas (2015) (1)
- Treatment with bevazicumab and liposomal doxorubicin for recurrent high-grade gliomas (HGGs). (2010) (1)
- Association of TP53 codon 72 polymorphism with TP53 mutation in triple-negative breast cancer (TNBC) patients. (2014) (1)
- P4-17-05: Brain Metastasis Free Survival (BMFS) Differs between Breast Cancer Subtypes. (2011) (1)
- Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial (2020) (1)
- 2928 Laboratory parameters have independent prognostic impact in patients with newly diagnosed brain metastases: analysis of 1201 cases (2015) (1)
- How I treat cancer special issue (2019) (1)
- - Deoxycytidine and Trichostatin A in Multiple Myeloma Cells ′ Genome-Wide Transcriptional Response to 5-Aza-2 (2007) (1)
- An Experimental Therapeutic Approach: Clinical and Immunological Aspects of Plasmapheresis (1987) (1)
- Descriptive analysis of 2419 patients with brain metastases of solid cancers: A real life cohort. (2016) (1)
- 3046 POSTER A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX6 + Cetuximab versus FOLFIRI + Cetuximab as first-line therapy in patients with metastatic colorectal cancer (2007) (1)
- Clinical considerations in the optimisation of gemcitabine plus taxane as first-line treatment for metastatic breast cancer (2007) (1)
- Programmed and aleatory elements in thymic leukemia. (1981) (1)
- 114 The dual PI3K/mTOR blocker NVP-BEZ235 sensitizes cancer cells against irreversible ErbB inhibitors (2010) (1)
- Abstract PS2-01: Plk1 expression & efficacy of palbociclib in advanced hormonal receptor-positive breast cancer patients from PEARL study (GEICAM 2012-03) (2021) (1)
- Factor V Leiden Mutation Increases the Risk of Venous Thromboembolism in Cancer Patients – Results From the Vienna Cancer and Thrombosis Study (CATS). (2012) (1)
- Rationale of an economically driven PD1 biomarker development in lung cancer—an academic dilemma (2016) (1)
- PD-L1 expression and tumor infiltrating lymphocytes (TIL) in brain metastases (BM) of small cell lung cancer (SCLC). (2016) (1)
- BRCA-1 promotor methylation as predictor of benefit from adjuvant CMF in triple-negative breast cancer not responsive to taxane-based neoadjuvant chemotherapy. (2013) (1)
- Induction of immunomediated diseases by recombinant human granulocyte-macrophage colony-stimulating factor during cancer treatment? (1999) (1)
- Safety and efficacy of pazopanib in heavily pretreated and treatment-naive patients with metastatic renal cell carcinoma (mRCC): A single center experience of the Medical University of Vienna, Austria. (2012) (1)
- High-dose chemotherapy plus hematopoietic stem-cell rescue for metastatic breast cancer. (2000) (1)
- Shift in phenotype of acute T-lymphocytic leukemia to eosinophilic leukemia: a case report. (1988) (1)
- Systemic therapy and overall survival (OS) in patients (pts) with brain metastases from HER2-positive (HER2+) metastatic breast cancer (MBC). (2011) (1)
- SC22.04 How Can Immunotherapy Be Implemented in a Cost-Effective Strategy? (2017) (1)
- P2.15-03 Availability and Reimbursement of Diagnostic Testing and Novel Anti-Cancer Drugs for NSCLC in CEE: Results of a CECOG Survey (2018) (0)
- FC5.02 BREAST CANCER: DIAGNOSIS AND TREATMENT FC5.02.01 VALUE OF FUNCTIONAL BLOOD SUPPLY PAlTERN ANALYSIS IN THE DETECTION OF EARLY BREAST CANCER (2003) (0)
- [Immunization by way of the root canal, sign of a focal process (proceedings)]. (1976) (0)
- Initiation of the TURANDOT breast cancer study (2009) (0)
- Effect of laboratory parameters on prognostic value in patients with newly diagnosed brain metastases: Analysis of 1,207 cases. (2015) (0)
- Time interval between final protocol approval (FPA) and inclusion of the first patient into randomized clinical trials (RCTs) performed by the Central European Cooperative Oncology Group (CECOG): A 10-year experience. (2016) (0)
- 85 P - Modulation of decreased adhesion molecule expression on breast cancer cell lines in vitro (1996) (0)
- Gene expression profiling of multiple myeloma cell lines after treatment with 5-aza-2′deoxycytidine and Trichostatin A (2005) (0)
- [Chemotherapy of malignant adrenal gland tumors]. (1988) (0)
- Establishment of a Secretome Database of Primary and Cultured Cells for Biomarker Discovery (2008) (0)
- FRI-07 Modern systemic drug therapies in breast cancer in 2013 (2013) (0)
- Letter from the Editor (2011) (0)
- 2926 Tumor-infiltrating lymphocytes (TILs) and PDL1 expression in lung cancer brain metastases (2015) (0)
- CECOG News (2008) (0)
- P-177Phase II trial of capecitabine + nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma (2015) (0)
- Overall survival with cetuximab every-2-weeks versus standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumour location. (2022) (0)
- [Fasciitis with eosinophilia--a case report]. (1982) (0)
- Efficacy of the Combination of Bortezomib and Dexamethasone in Systemic AL Amyloidosis. (2009) (0)
- Abstract 3189: Aggressive renal cancer cell behavior is partly mediated by CD98hc (2010) (0)
- Pantsuits Debut in Laboratories (1970) (0)
- Vaccine her-2 / neu multi-peptide. (2006) (0)
- Abstract A5: Characterization of signaling pathways related to resistance of breast cancer cells against irreversible EGFR/HER/ErbB kinase inhibitors (2010) (0)
- Mimotopes of the disialoganglioside GD2 elicit anti-GD2 antibodies recognising GD2 on melanoma cells. (2006) (0)
- European Society for Medical Oncology 2012 annual meeting: update on oncology trials (2013) (0)
- Translating the molecular analysis of cancer biology into therapeutic concepts. (2014) (0)
- 559 POSTER The role of the ErbB3/PI3K/AKT pathway in determining breast cancer cell sensitivity against the irreversible dual EGFR/ErbB2 inhibitor EKB-569 (2008) (0)
- [The influence of surgery upon leucocyte function (author's transl)]. (1978) (0)
- 1 BACKGROUND AND IMPLEMENTATION PLAN FOR THE EUROPEAN CANCER PATIENT’S BILL OF RIGHTS, 2016 (ARCHIVE) ECC Members (2017) (0)
- Comparative 99 mTc-MIBI , 99 mTc-tetrofosmin and 99 mTc-furifosmin uptake in human soft tissue sarcoma cell lines (0)
- Low HER2-expression to predict impaired activity of endocrine therapy in patients with estrogen-receptor (ER) positive metastatic breast cancer (MBC). (2013) (0)
- 84 P - Tissue expression and serum levels of HER-2/neu in patients with breast cancer (1995) (0)
- Brustkrebs: Bevacizumab / Capecitabin vs. Bevacizumab / Paclitaxel (2016) (0)
- ESMO Open welcomes the association with the Japanese Society of Medical Oncology (JSMO) (2017) (0)
- Intensified local treatment and systemic therapy significantly increase time to progression and survival in patients with brain metastases from advanced breast cancer. (2006) (0)
- Mastectomy and immediate reconstruction: a good option ? (1994) (0)
- Darbepoetin &agr; as treatment for anemia in patients receiving chemotherapy: a single-center experience (2005) (0)
- Editorial Board / Contents / Guidelines (2014) (0)
- P-52 Overall survival with cetuximab every 2 weeks vs standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumor location (2021) (0)
- [Adjuvant hormonal therapy in lymph node-negative breast carcinoma patients in the postmenopause]. (1992) (0)
- Abstract C195: CD98hc (SLC3A2) is a central regulator of renal cancer cell behavior. (2013) (0)
- High Soluble P-Selectin and Low Platelet Count as Thrombosis Risk Markers in Glioma Patients. (2009) (0)
- Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers (2022) (0)
- Anti-thymocyte globulin overdosage--risk or potential benefit? (1988) (0)
- Clinical trial design issues: Session 1 (2007) (0)
- [Leukocyte migration inhibition with collagen in chronic polyarthritis patients and controls]. (1978) (0)
- Prognostic impact of breast cancer (BC) subtype in elderly patients. (2015) (0)
- Temporal muscle thickness (TMT) is an independent prognostic parameter in patients with newly diagnosed brain metastases (BM) of breast cancer (BC) (2016) (0)
- Phase II study: WBRT ±temozolomide (TMZ) in patients with multiple brain metastases from non-small cell lung cancer (NSCLC). (2009) (0)
- Resistance to TRAIL induced apoptosis based on methylation of TRAIL receptor 1 (DR4) and its relevance for a potential treatment option for ovarian cancer (2005) (0)
- Saudi lung cancer management guidelines 2017: Improving lung cancer care in Saudi region (2017) (0)
- Editorial Board / Contents / Guidelines (2014) (0)
- Assessment of the Potential of Immature CD19+CD21- B-Lymphocytes to Predict Response to Various Systemic Therapies in Chronic Graft-Versus-Host Disease. (2009) (0)
- Correlations between Self-Rated Fatigue with Quality of Life, and Social Participation in Viennese Outpatients Suffering from Advanced Cancer During Palliative Chemotherapy (2005) (0)
- Abstract 2380: Carcinoembryonic antigen (CEA) directly activates endothelial cells, thereby inducing (tumor)-angiogenesis (2010) (0)
- There is more to some EGF receptor inhibitors - PD153035 reveals triple action: EGF receptor inhibition, DNA-intercalation, RAR-beta induction (2007) (0)
- Abstract 406: Effects of an RGD peptide in osteoclast maturation and behavior as a therapeutic option for metastatic bone disease (2015) (0)
- 22P Active immunization with a multi-peptide B cell vaccine, targeting trastuzumab and pertuzumab binding sites, prevents the formation of Her-2/neu-expressing lung metastases (2022) (0)
- Expansion of Immature/Transitional B-Lymphocytes in Patients with Active Chronic Graft-Versus-Host Disease. (2007) (0)
- Vaccination with a CEA epitope mimic leads to reduced growth of tumor transplants (2007) (0)
- «Targeted Therapies» in der Behandlung von Brustkrebs (2008) (0)
- Reply to the letter to the editor 'The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice' by Hartmann and the letter 'Comment on ESMO Magnitude of Clinical Benefit Scale' by Muhonen et al. (2016) (0)
- Abstract 397: Transcriptional regulation of SPAG6 by DNA methylation in NSCLCs (2014) (0)
- Abstract 4257: Genome-wide CpG island methylation analysis identifies tumor specifically methylated genes in non-small cell lung cancer patients. (2013) (0)
- Exploratory analyses of candidate predictive and prognostic tissue biomarkers (BMs) in the open-label randomised phase III TANIA trial of bevacizumab (BEV) in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC) (2016) (0)
- Comprar Drugs For Her-2-Positive Breast Cancer | M. Sibilia | 9783034600934 | Springer (2011) (0)
- CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer (2023) (0)
- A Phase II Randomized Study of Doxorubicin Alternated With Docetaxel vs Sequential Administration of Four Cycles of Docetaxel Followed by Four Cycles of Doxorubicin as First-Line Chemotherapy in Metastatic Breast Cancer Patients (2000) (0)
- Correlation of large brain edema with favorable prognosis in patients with single brain metastases. (2012) (0)
- Abstract 3151: Active immunization with PD1-derived mimotope-Combination immunotherapy against Her-2/neu-expressing tumors (2020) (0)
- Review of achievments (2009) (0)
- CECOG’s services at a glance (2010) (0)
- Severe thrombocytopenia after the first cycle of temozolomide: Who is at risk? (2008) (0)
- Reply to the letter to the editor 'ESMO-MCBS v1.1: statistical and patient relevant shortcomings' by Emprechtinger et al. (2018) (0)
- Abstract 4110: Identification of PD1 B cell mimotopes with functional PD1-PDL1 blocking capacity: New strategy for cancer immunotherapy (2019) (0)
- The ExtraMED biomedical periodicals library and HIV/AIDS (1999) (0)
- Computerized mimotope surface scan identifies the cetuximab epitope on EGFR (2005) (0)
- Secretomes of Differently Stimulated Human Dendritic Cells Generated by 2D-PAGE and Shotgun Analysis (2008) (0)
- Abstract #722: A HER2 multi-peptide virosome vaccine induced HER-2 specific antibodies in patients with metastatic breast cancer: final results of a phase I study to evaluate safety and immunogenicity (2009) (0)
- In vivo Tube Assay: An Optimised Protocol of the Directed in vivo Angiogenesis Assay by Implementing Immunohistochemistry (2015) (0)
- [Initial clinical experiences in a large Austrian patient sample with immunodeficiency syndrome (AIDS): I. Type and course of encountered infections]. (1988) (0)
- tumor infiltrating lymphocytes in glioblastoma Running title : PD-L 1 expression in glioblastoma (2017) (0)
- [Increase of dehydroepiandrosterone sulfate and prolactin during plasmapheresis]. (1985) (0)
- 556PINTEGRIN BETA-3 GENETIC VARIANTS PREDICT THE RISK OF THROMBO-EMBOLIC EVENTS IN PATIENTS WITH COLORECTAL CANCER. (2014) (0)
- 107 P - Results of a randomized adjuvant breast cancer trial comparing a conventional with a perioperative start of chemotherapy (1996) (0)
- Use of the ErbB2/CEP17 ratio to predict prognosis and response to trastuzumab-based therapy in the metastatic breast cancer setting. (2009) (0)
- Abstract 2766: Genome-wide miRNA methylation analyses in non-small cell lung cancer patients (2016) (0)
- One year of ESMO Open: Cancer Horizons—where are we going from here? (2016) (0)
- Increase in CEA in dependence of the estrogen receptor status in patients with metastatic breast cancer (1993) (0)
- 'Value for money' requirement in treatment choices. (2002) (0)
- Predictive value of baseline CD66e/CEA serum levels on efficacy of bevacizumab-based treatment in advanced colorectal cancer. (2013) (0)
- oral vaccination with tumor antigen mimotopes naked. (2002) (0)
- Abstract OT1-03-04: A phase 2 study of abemaciclib in patients with brain metastases secondary to hormone receptor positive breast cancer (2016) (0)
- Optimal Sequencing of Anti-HER2 Therapy (2014) (0)
- Reply to the letter to the editor 'Addressing the quality of the ESMO-MCBS' by Del Paggio. (2017) (0)
- Natural killer cell activity and antibody-dependent cellular cytotoxicity in recent-onset type I diabetes mellitus: a follow-up study under cyclosporin A treatment (1986) (0)
- OT3-01-04: TANIA: A Randomized Phase III Trial Evaluating Continued and Reintroduced Bevacizumab (BEV) in Patients Previously Treated with 1st-Line BEV for Locally Recurrent/Metastatic Breast Cancer (LR/mBC). (2011) (0)
- The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients (2019) (0)
- Phase II study on the efficacy and safety of lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu: Positive advanced breast cancer (CECOG LaVie Trial). (2015) (0)
- Fulvestrant (F) as first-line palliative treatment for hormone receptor (HR)- positive metastatic breast cancer. (2010) (0)
- Letter to the editor (1998) (0)
- Making treatment choices: A physician[apos ]s discussion of patients[apos ] needs (2003) (0)
- oral vaccination with tumor antigen mimotope gin-met-trp-ala-pro-trp-gly gin pro-asp-. (2003) (0)
- Relationship of 4F2hc expression and grade of malignancy in renal cell cancer (RCC). (2011) (0)
- [Immunopathogenesis and therapeutic approaches in acquired immunologic deficiency syndrome (AIDS)]. (1987) (0)
- 366PACTIVITY OF T-DM1 IN HER2-POSITIVE BREAST CANCER BRAIN METASTASES. (2014) (0)
- 5053 POSTER Randomized Phase III Study of First-line Bevacizumab in Combination With Capecitabine or Paclitaxel for HER2-negative LR/MBC: Interim Safety Data (2011) (0)
- Characterisation of oncologic patient visits at the ED at an Austrian tertiary care center. (2018) (0)
- 261 Multi-epitope peptide vaccine and co-administration of IL-12 prevents tumor growth in Her-2 transgenic mice (2004) (0)
- Identification of epigenetically silenced genes in lung adenocarcinoma cell lines (2007) (0)
- Impaired production of tumour necrosis factor‐α, defective expression of ICAM‐1 in healthy women with germline mutations of BRCA1 (2000) (0)
- Activity of T-DM1 in Her2-positive breast cancer brain metastases (2015) (0)
- 563 Pharmacokinetics of epirubicin and paclitaxel during weekly administration in patients with metastasised breast cancer (2003) (0)
- CECOG at ASCO 2009 (2009) (0)
- Neoadjuvant chemotherapy in locally advanced gastric cancer with epirubicin, oxaliplatin, and capecitabine (EOX): A retrospective analysis. (2010) (0)
- Combination of oral idarubicin and cyclophosphamide in the treatment of advanced breast cancer (1998) (0)
- 27 P - Second line chemotherapy with modulation of drug resistance in patients with advanced soft tissue sarcoma (1996) (0)
- Abstract #4419: HER receptors and fatty acid synthase in ovarian cancer: Molecular rationales for co-targeting approaches (2009) (0)
- PD PHASE III TRIAL EVALUATING THE ADDITION OF BEVACIZUMAB TO ENDOCRINE THERAPY AS FIRST-LINE TREATMENT FOR ADVANCED BREAST CANCER : THE GEICAM / GBG LEA STUDY (2012) (0)
- Trastuzumab mimotope vaccination of HER-2/neu transgenic mice results in prolonged tumor-free survival and reduced tumor load. (2006) (0)
- Abstract P1-08-40: BRCA-1 promotor methylation and p53 mutation in triple-negative breast cancer patients refrectory to taxane-based neoadjuvant chemotherapy (2013) (0)
- The concept of comprehensive cancer centres of medical universities: A summary of thoughts (2011) (0)
- Contents Vol. 69, 2005 (2006) (0)
- Etiologic and Pathogenetic Aspects of Systemic Lupus Erythematosus: A Critical Approach (1987) (0)
- Ukraine's neighbouring countries accept the burden of cancer care for refugees. (2022) (0)
- TGFß1 signalling in human insulinomas compared with human islets. (2007) (0)
- Analysis of risk factors predicting time to development of brain metastases (2008) (0)
- Natural killer cell function in adolescent and adult schizophrenic patients (1993) (0)
- HER-2 / neu peptide vaccine Multi (2006) (0)
- Editorial Board / Contents / Imprint / Guidelines (2014) (0)
- Public perception of cancer care in Poland and Austria: A survey study. (2014) (0)
- Capecitabine (Cap) monotherapy in anthracycline (A)/taxane (T)-pretreated MBC. (2011) (0)
- Bevacizumab apparently shows activity in the management of brain metastases, but currently clinical (2013) (0)
- Abstract P6-14-01: Final results of the TANIA randomized phase III trial of bevacizumab (BEV) after progression on 1st-line BEV therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC) (2016) (0)
- Biologic activities of trail in soft tissue sarcoma cell lines: induction of apoptosis and interaction with cytotoxic agents (2001) (0)
- 335 Proteome profiling of multiple myeloma and the associated microenvironment in bone marrow (2008) (0)
- Contents Vol. 70, 2006 (2007) (0)
- Favorable Survival of Multiple Myeloma Patients with t(11;14)(q13;q32) Plus Normal Chromosome 13q. (2004) (0)
- Abstract 4828: Genome-wide DNA methylation analysis identifies tumor-specifically methylated genes in non-small cell lung cancer patients (2011) (0)
- Abstract 424: Interference with alphaVbeta3 integrins via cyclic RGD peptides affects breast cancer cell behavior (2011) (0)
- Prognostic value of tumor markers CA 15-3 and CEA during fulvestrant treatment (2005) (0)
- 28. Influence of cytostatic agents on the entry of radiolabelled low-density lipoprotein (LDL) into the arterial wall (1994) (0)
- Early vs. late treatment with darbepoetin alfa in patients with genitourinary tumors during chemotherapy. (2006) (0)
- Characterization of candidate tissue and blood biomarkers in a rare cohort of myxopapillary ependymoma patients. (2013) (0)
- Soluble CD87 (s-uPAR) predicts bevacizumab-based first line treatment of metastatic colorectal cancer (mCRC): Results from a prospective multi-center study. (2017) (0)
- Individualized treatment schedule and investigator 's defined time to resistance (TTRi) may prolong survival in patients with metastatic renal cell carcinoma (mRCC) (2015) (0)
- Announcing the ESMO Open special issue on upcoming molecular targets for cancer treatment (2020) (0)
- Impact of HER2-targeted therapy on overall survival (OS) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC). (2011) (0)
- Abstract LB-177: First-line bevacizumab (BEV) + chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): Subgroup analysis of the open-label non-inferiority TURANDOT phase III trial. (2013) (0)
- Poster Presentation: P-37. Changes in Natural Killer Cell Activity and Antibody-Dependent Cellular Cytotoxicity with Menopause (1994) (0)
- [Internal medicine aspects of acquired immune deficiency syndrome]. (1990) (0)
- Is Brain-Only Metastatic Breast Cancer A Distinct Entity? (2012) (0)
- PO-32 Prediction of venous thromboembolism in cancer patients by measuring thrombin generation – Results from the Vienna Cancer and Thrombosis Study (CATS) (2010) (0)
- Abstract CT083: Tumor-agnostic efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: ROAR basket study (2023) (0)
- 6571 POSTER Open-label study of pemetrexed (P) alone or in combination with a platinum in patients (pts) with peritoneal mesothelioma (PM): results from the international expanded access program (EAP) (2007) (0)
- Subject Index Vol. 70, 2006 (2007) (0)
- Abstract 4360: CD87 is essential for mediating growth-factor induced angiogenesis via distribution of integrin beta-1 (2012) (0)
- Abstract PD10-04: An ERBB2 Gene Dosage Effect Confers Biological Aggressiveness to Breast Cancers and Trastuzumab Sensitivity in Patients with Metastatic Disease (2010) (0)
- Novel systemic therapy in advanced non-small-cell lung cancer (2016) (0)
- Antiangiogenic treatment approaches in breast cancer (2013) (0)
- Reduced antibody levels and high seronegativity rates against vaccine preventable diseases pose a risk factor for infections in patients with solid and hematologic cancers (2019) (0)
- CCNE1 mRNA and cyclin E1 protein expression as predictive biomarkers for efficacy of palbociclib plus fulvestrant versus capecitabine in the phase III PEARL study. (2021) (0)
- Pro-BNP for detection of sunitinib-induced cardiac toxicity in patients with renal cell carcinoma. (2010) (0)
- Abstract P6-06-40: Analysis of outcome according to risk factors in the randomized phase III TURANDOT trial evaluating first-line bevacizumab-containing therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC) (2013) (0)
- PP97 The human carcinoembryonic antigen (CEA) predicts therapeutic response towards VEGF-targeting therapies in colorectal cancer (2009) (0)
- CSCO joins ESMO Open—Cancer Horizons (2016) (0)
- Tumor-infiltrating lymphocytes (TILs) and expression of PD-L1 in melanoma brain metastases (BM). (2014) (0)
- Reply to A. Bamias et al (2009) (0)
- Budget projections and clinical impact of an immuno-oncology class of treatments: Experience in four EU markets. (2021) (0)
- Analysis of XPD gene Lys751Gln polymorphism as predisposing factor for non-small cell lung cancer (NSCLC) development: P2-012 (2007) (0)
- Management of Breast Cancer? What Are the Current Standards of Care and Recent Developments in the (2013) (0)
- Subject Index Vol. 60, 1994 (1994) (0)
- Decreased body mass index (BMI) associates with impaired survival from diagnosis of brain metastases in lung cancer patients: analysis of 624 patients (2016) (0)
- [Impact of oncologic therapeutic concepts 2004]. (2004) (0)
- 177 O - A prospective randomized trial on neoadjuvant and adjuvant chemo- and radiotherapy in primarily inoperable soft tissue sarcoma (1996) (0)
- Reply to Capecitabine dosing is not yet optimized for breast cancer (2010) (0)
- Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC). (2011) (0)
- Reply to the Correspondence by Untch et al. "Concerning Dediu M, Zielinski C: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer" [Breast Care 2019; DOI 10.1159/000500624]. (2019) (0)
- Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide (2017) (0)
- 482 Analysis of risk factors associated with early development of brain metastases in breast cancer (2010) (0)
- αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer (2014) (0)
- memo: Official journal of the OeGHO and CECOG (2017) (0)
- memo – New official Journal of CECOG (2008) (0)
- Inhibiting Melanoma Cell Growth In Vitro Mimotope Induces a Humoral Response Weight Melanoma-Associated Antigen Vaccination with a Human High Molecular (2004) (0)
- 590 POSTER Molecular and antiproliferative effects of inhibitors of fatty acid synthase and of ErbB receptors in ovarian cancer cells (2008) (0)
- The importance of estrogen receptor concentration as a prognostic factor in postmenopausal breast cancer patients (1987) (0)
- Reply to the letter to the editor 'Utilisation of the ESMO-MCBS in practice of HTA' by Wild et al. (2016) (0)
- HER3 expression in the primary tumor as marker of metastatic potential in breast cancer patients. (2012) (0)
- P08.01RESPONSE TO T-DM1 IN HER2-POSITIVE BREAST CANCER BRAIN METASTASES (BM) (2014) (0)
- The Paternally Expressed Gene 10 (PEG10) on Chromosome 7q21 Is Overexpressed and Imprinted in High-Risk B-CLL. (2005) (0)
- Circulating B-Lymphocyte Subpopulations as Novel Biomarker for Measuring Activity of Chronic Graft-Versus-Host Disease. (2006) (0)
- Targeting of Heat Shock Protein 32 (Hsp32) in Neoplastic Cells by Styrene Maleic Acid Zinc Protoporphyrin (SMA-ZnPP) Is Associated with Reduced Growth and Induction of Apoptosis. (2006) (0)
- Abstract #297: Loss of JunB and cJun in NPM-ALK induced ALCL results in loss of PDGFRß expression and increased survival advantage. (2009) (0)
- 143P Quality of life (QoL) with palbociclib (PAL) plus endocrine therapy (ET) versus (vs) capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL study (2020) (0)
- Association of TP53 mutations with TP53 codon 72 polymorphism and outcome in triple-negative breast cancer (2016) (0)
- Subject Index Vol. 56, 1992 (1992) (0)
- Subject Index Vol. 69, 2005 (2006) (0)
- Thymic epithelium determines preleukemic cellular and virological changes in leukemia-susceptible mice: studies on bone marrow and thymic chimeras. Abstr. (1981) (0)
- The ESMO-Magnitude of Clinical Benefit Scale (MCBS) in rare tumor entities: A real life experience at the Medical University Vienna (2016) (0)
- A cross-section questionnaire to evaluate patients' satisfaction with totally implanted access ports (Port-a-Cath; PAC) and analysis of PAC-related complications at a tertiary care center. (2013) (0)
- Single administration of pegylated filgrastim once per cycle compared to daily filgrastim in patients with primary breast cancer receiving neoadjuvant chemotherapy (2005) (0)
- Shifts in phenotype of dendritic cells (DC) in healthy BRCA1 mutation carriers and in patients with early breast cancer (2001) (0)
- D-dimer levels and prediction of overall survival in cancer patients. (2010) (0)
- Mimotopes d'antigene et vaccin contre des affections cancereuses (2002) (0)
- Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts. (1981) (0)
- US 6 , 995 , 171 B 2 1 BICYCLIC PYRIMDINE AND PYRIMIDINE DERVATIVES USEFUL AS ANTICANCER AGENTS (2017) (0)
- Abstract 2772: SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers (2016) (0)
- [Internal and neurologic manifestations of the acquired immunodeficiency syndrome]. (1988) (0)
- Combination of trastuzumab and gemcitabine as salvage therapy in heavily pretreated patients with metastatic breast cancer (2008) (0)
- Plaque-forming cells inhumancordblood: studies onTandBcell function (1980) (0)
- 447 Extended Analysis for Cancer Treatment (EXACT): Interim analysis of a prospective precision medicine trial (2015) (0)
- Characterization of oncologic patient visits at the emergency department (ED) at an Austrian tertiary care center. (2019) (0)
- Fractal growth kinetics of breast cancer cells (2000) (0)
- Predicting response to second-line trastuzumab-based therapy in patients (pts) with HER2-positive advanced breast cancer (ABC) (2009) (0)
- Abstract 122: MiR-9-3 and miR-193a are targets for DNA methylation in non-small cell lung cancers (2012) (0)
- CD98hc (SLC3A2), a novel biomarker correlating with grade of malignancy in renal cell cancer. (2012) (0)
- Modulation in phenotype and function of dendritic cells in early breast cancer (2001) (0)
- 2923 Role of endocrine therapy in breast cancer (BC) patients with brain metastases (2015) (0)
- Aspects of altered immunefunctions in breast cancer patients (1993) (0)
- Reply to the letter to the editor 'Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies'. (2017) (0)
- Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel (2017) (0)
- [Intravenous substitution with immunoglobulins]. (1991) (0)
- Abstract 2306: Quantitative assessment of one-side directed in vivo angiogenesis (2015) (0)
- Monocyte functions following treatment with colony stimulating factors in patients with advances testicular cancer undergoing autologous bone arrow transplantation (1994) (0)
- Reply to the letter to the editor 'Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?' by Del Paggio. (2018) (0)
- ErbB2/CEP17 and total ErbB2 copy number as independent forecast factor for time to First Metastasis (TTM) and with a trastuzumab-based therapy in HER2 testing metasase breast cancer [abstract] (2010) (0)
- Association of large cells in spleens of mutant hrs/j mice with abnormal t-cell development in the preleukemic state. Abstr. (1981) (0)
- Abstract C3: Tumor-derived soluble uPAR regulates tumor angiogenesis via PTEN. (2013) (0)
- [The use of erythropoiesis-stimulating proteins in anemic patients with malignant diseases]. (2008) (0)
- Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. (2023) (0)
- Book Reviews / News Items (1967) (0)
- P04.03 Analysis of the inflammatory tumor microenvironment in meningeal malignancies. (2016) (0)
- PO-36 A high platelet count independently predicts venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS) (2007) (0)
- The epidermal growth factor-receptor inhibitor PD153035 upregulates retinoic acid receptor-beta by epigenetic mechanisms (2006) (0)
- Contents, Vol. 54, 1997 (1995) (0)
- A randomized adjuvant breast cancer trial comparing conventional with perioperative initiation of chemotherapy (1997) (0)
- MONDTI: Molecular characterisation platform for identifying actionable mutations in advanced or metastatic cancers (2016) (0)
- [Effect of hormone receptors on the site of metastases in breast cancer]. (1987) (0)
- Abstract 430: 4F2hc mediates renal cancer cell (RCC) behavior (2011) (0)
- Integrin genetic variants and risk of thromboembolic events in patients with colorectal cancer. (2014) (0)
- Recognized by Trastuzumab on the Generation of Peptide Mimics of the Epitope (2013) (0)
- Abstract 177: MicroRNA expression profiling in non-small cell lung cancer cells treated with 5-aza-2′-deoxycytidine and trichostatin A (2010) (0)
- Vaccination of cancer patients with whole-virion, adjuvant-free pandemic influenza H1N1 vaccine: Patient acceptance and vaccine immunogenicity. (2011) (0)
- Letter to the Editor (2002) (0)
- Trastuzumab as Intellectual, Medical and Economical Challenge (2006) (0)
- Gemox Plus Erlotinib for the Treatment of Metastatic Pancreatic Adenocarcinoma (2012) (0)
- Next Generation Sequencing Identifies DNA Methylation Patterns Indicative of Disease Progression in Ph+ CML (2014) (0)
- Perspectives for Cancer Care and Research in Central and Eastern Europe (2022) (0)
- [The meaning of the carcinoembryonic antigen]. (1995) (0)
- OT2-01-02: First-Line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER2−Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): A Randomized Phase III Trial. (2011) (0)
- Active immunization with immune checkpoint inhibitors-mimotope elicits strong anti-tumour effect against HER-2/neu-expressing tumours (2019) (0)
- [Natural cellular immunity as the effector mechanism in tumor defense]. (1987) (0)
- X-Linked Inhibitor of Apoptosis Protein (XIAP) Supports Urokinase (uPA)-Induced Endothelial Cell Survival (2008) (0)
- Brain metastases: pathobiology and emerging targeted therapies Matthias PreusserDavid CapperAysegul Ilhan-MutluAnna Sophie Berghoff • Peter BirnerRupert BartschChristine MarosiChristoph Zielinski • Minesh P. MehtaFrank WinklerWolfgang WickAndreas von Deimling (2012) (0)
- 178 P - A randomized trial of adjuvant treatment of soft tissue sarcomas by either radiotherapy or radiotherapy + ifosfamide, adriblastin and DTIC (IFADIC) intensified by the use of G-CSF (1996) (0)
- Carcinoembryonic Antigen (CEA) Regulates Tumor-Angiogenesis in Colon Carcinomas. (2008) (0)
- Vaccine cancers that are associated with the HER-2 / neu (2001) (0)
- SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers (2017) (0)
- Locally advanced gastric cancer treated with neoadjuvant chemotherapy: Epirubicin, oxaliplatin, and capecitabine (EOX). (2011) (0)
- relapsed/refractory mantle cell lymphoma Anti-tumor activity of rituximab plus thalidomide in patients with (2013) (0)
- Urokinase-Type Plasminogen Activator Receptor (uPAR, CD87) Regulates Integrin Redistribution in Endothelial Cells Via Interaction with Low Density Lipoprotein Receptor- (LDLR-) Like Proteins (2011) (0)
- Future Directions in the Treatment of Breast Cancer – Cellular Interventions Using Dendritic Cells (2003) (0)
- Subject Index Vol. 54,1997 (1997) (0)
- 903 Capecitabine-monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma (2003) (0)
- Making treatment choices: a physician's discussion of patients' needs. (2003) (0)
- [Current status of immunotherapy in oncology]. (1991) (0)
- Abstract CT059: A Phase Ib open label multicenter study with a HER2/neu peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy shows safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced cancer of the stomach (2019) (0)
- Mimotope vaccination for epitope-specific induction of “Herceptin-like” anti-HER-2 antibodies (2005) (0)
- Bortezomib Administered Subcutaneously Is Well Tolerated in Bortezomib-Based Combination Regimens Used in Patients with Multiple Myeloma and AL Amyloidosis (2011) (0)
- Vaccination with peptides derived from the extracellular domain of Her-2/neu elicits specific humoral and cellular immune responses in mice (2001) (0)
This paper list is powered by the following services:
Other Resources About Christoph Zielinski
What Schools Are Affiliated With Christoph Zielinski?
Christoph Zielinski is affiliated with the following schools:
